Instem (INS.L) Stock Price
Instem Price
Revenue has compounded at 14.1% per year over the past 15 years to 57.63 M GBP. Earnings per share have declined at 8.5% per year over the last 15 years. Instem's net margin stands at 8.2%, up from 6.5% several years earlier.
Instem stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Instem over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Instem stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Instem's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Instem Price |
|---|
Instem Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Instem Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM GBP |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM GBP |
| EBITM GBP |
| EBIT MARGIN% |
| NET INCOMEM GBP |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.00 | 10.00 | 11.00 | 13.00 | 16.00 | 18.00 | 21.00 | 22.00 | 25.00 | 28.00 | 46.00 | 57.00 | 67.00 | 75.00 | 81.00 | 90.00 |
| – | – | 10.00 | 18.18 | 23.08 | 12.50 | 16.67 | 4.76 | 13.64 | 12.00 | 64.29 | 23.91 | 17.54 | 11.94 | 8.00 | 11.11 |
| 100.00 | 100.00 | 100.00 | 100.00 | 93.75 | 94.44 | 90.48 | 95.45 | 96.00 | 92.86 | 95.65 | 77.19 | 95.65 | 95.65 | 95.65 | 95.65 |
| 10.00 | 10.00 | 11.00 | 13.00 | 15.00 | 17.00 | 19.00 | 21.00 | 24.00 | 26.00 | 44.00 | 44.00 | 64.09 | 71.74 | 77.48 | 86.09 |
| 1.00 | 1.00 | – | – | 1.00 | – | – | 2.00 | 2.00 | 3.00 | 4.00 | 6.00 | 9.00 | 11.00 | 6.00 | 21.00 |
| 10.00 | 10.00 | – | – | 6.25 | – | – | 9.09 | 8.00 | 10.71 | 8.70 | 10.53 | 13.43 | 14.67 | 7.41 | 23.33 |
| 1.00 | 1.00 | – | – | – | 1.00 | – | 1.00 | – | 2.00 | 1.00 | 4.00 | 7.00 | 9.00 | 9.00 | 13.00 |
| – | – | – | – | – | – | – | – | – | – | -50.00 | 300.00 | 75.00 | 28.57 | – | 44.44 |
| 11.85 | 11.76 | 11.78 | 12.22 | 12.40 | 15.63 | 16.16 | 16.85 | 16.25 | 19.65 | 22.72 | 23.69 | 23.69 | 23.69 | 23.69 | 23.69 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Instem generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Instem retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Instem's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Instem has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Instem's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Instem stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Instem Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Instem business model & stock analysis
Instem SWOT Analysis
Strengths
Instem PLC possesses several strengths that contribute to its success in the market. These include:
- Strong financial performance and stability
- Wide range of innovative and high-quality software solutions
- Well-established reputation and extensive industry knowledge
- Global presence with a strong customer base
- Experienced and skilled workforce
Weaknesses
Despite its strengths, Instem PLC also faces certain weaknesses that could pose challenges. These include:
- Dependence on specific industries for revenue
- Limited product diversification
- Reliance on key clients for a significant portion of sales
Opportunities
Instem PLC can capitalize on the following opportunities to further grow and expand its business:
- Increasing demand for software solutions in the life sciences industry
- Expansion into emerging markets with untapped potential
- Acquisition of complementary businesses to enhance product portfolio
- Technological advancements providing new avenues for innovation
Threats
However, there are certain threats that Instem PLC needs to consider and mitigate:
- Intense competition from established software providers
- Economic downturns impacting customer spending
- Changing regulations and compliance requirements
- Vulnerability to data breaches and cybersecurity risks
Instem Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Instem historical P/E ratio, EBIT multiple, and P/S ratio
Instem annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Instem shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
EESG©
Eulerpool ESG Scorecard© for the Instem stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Instem shareholder structure
| % | Name |
|---|---|
11.36577% | |
8.12131% | |
6.65436% | |
5.72869% | |
5.51633% | |
4.17780% |
Instem Beneficial Ownership Filings (SEC 13D/G)
Instem Executives and Management Board
7 members · avg. age 62 · 0 % women
Mr. Philip Reason
Chief Executive Officer, Executive Director
279,000.00 GBP
Management
Mr. Nigel Goldsmith
Chief Financial Officer, Company Secretary, Executive Director · since 2011
Mr. Tom Cooper
IR Contact Officer · since 2022
Board of Directors
Mr. David Gare
Non-Executive Chairman of the Board
Mr. Michael McGoun (72)
Non-Executive Independent Director
Mr. David Sherwin
Non-Executive Director · since 2010
Mr. Riaz Bandali (52)
Non-Executive Independent Director
Instem Supply Chain
Instem Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.62 | 0.60 | 0.89 | ||
| 2 | 0.71 | 0.66 | 0.85 | ||
| 3 | 0.70 | 0.68 | 0.84 | ||
| 4 | 0.72 | 0.72 | 0.78 | ||
| 5 | 0.32 | 0.22 | 0.78 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.41 | -0.42 | -0.72 | ||
| 2 | -0.61 | -0.21 | -0.68 | ||
| 3 | -0.26 | -0.50 | -0.43 | ||
| 4 | 0.71 | 0.47 | -0.21 | ||
| 5 | -0.52 | -0.64 | 0.18 |
Frequently asked questions about Instem
The main competitors of Instem PLC in the market include companies such as LabCorp, Medidata Solutions, Oracle Health Sciences, and Parexel International.
Instem PLC is a leading provider of software solutions and services for the life sciences industry. The company primarily operates through its informatics solutions which help organizations streamline their research and development processes. Instem's software products facilitate data management, analysis, and compliance across various stages of the drug discovery and development lifecycle. By offering comprehensive solutions, Instem PLC enables organizations to improve efficiency, enhance decision-making, and accelerate time-to-market for new therapies. With a strong focus on technological innovation and domain expertise, Instem PLC continues to drive advancements in the life sciences industry.
Instem PLC is primarily active in the healthcare and life sciences industry.
Instem PLC is a leading provider of software solutions and services to the global life sciences industry. With over 30 years of experience, Instem has established itself as a trusted partner in providing innovative technology solutions for drug development, regulatory compliance, and research management. Founded in 1987, Instem has grown to become a renowned player in the life sciences space, serving over 500 customers worldwide. The company's comprehensive suite of software solutions spans the entire research lifecycle, enabling organizations to enhance productivity, streamline processes, and drive operational excellence. Instem PLC's dedication to delivering cutting-edge solutions has solidified its position as a key player in the life sciences industry.
Instem PLC has achieved several significant milestones throughout its history. The company has successfully developed and delivered innovative software solutions for the life sciences industry. Instem PLC has been recognized for its contributions to the field, winning numerous industry awards and certifications. The company has formed strategic partnerships and collaborations, expanding its global reach and customer base. Instem PLC has also demonstrated consistent financial growth, with increased revenues and profitability over the years. Additionally, the company has received positive feedback from clients, reinforcing its reputation as a leading provider of software solutions for the life sciences industry.
Instem PLC is primarily present in the United Kingdom, United States, and in several European countries. The company operates globally, providing software solutions and services for the life sciences industry. With its headquarters in the UK, Instem PLC has established a strong presence in key markets, serving clients across North America, Europe, and other parts of the world. As a leading provider of scientific data solutions, Instem PLC offers its innovative products and expertise to support research organizations, pharmaceutical companies, regulatory authorities, and contract research organizations across these regions.
Instem PLC represents a strong set of values and a robust corporate philosophy. The company is committed to delivering innovative software solutions and services to the global life sciences industry. Instem fosters a culture of integrity, excellence, and collaboration to ensure the highest level of customer satisfaction. With a focus on advancing scientific research and improving regulatory compliance, Instem aims to enhance the efficiency and effectiveness of research organizations worldwide. By consistently prioritizing customer success and embracing technologies, Instem PLC is recognized as a leading provider of solutions that drive scientific knowledge and operational excellence in the life sciences domain.
9 analysts currently rate the Instem stock: 8 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Instem share trades at 9.69 EUR (8.30 GBP).
The Instem share (INS.L) is listed on 3 stock exchanges, including: Frankfurt (54I.F), London (INS.L), London (INS.L).
Instem PLC is a UK-based company specializing in software and information solutions for the life sciences sector. The company offers a wide range of products and services aimed at supporting and accelerating research and development processes. Translation: Instem PLC is a UK-based company specializing in software and information solutions for the life sciences sector. The company offers a wide range of products and services aimed at supporting and accelerating research and development processes.
The revenue cannot currently be calculated for Instem.
The profit cannot currently be calculated for Instem.
The P/E ratio cannot be calculated for Instem at the moment.
The P/S cannot be calculated for Instem currently.
The Eulerpool Quality Score for Instem is 5/10.
The ISIN of Instem is GB00B3TQCK30. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Instem is A1C7NS. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Instem is INS.L. The ticker symbol is used to trade Instem shares on the stock exchange.
Instem paid dividends every year for the past 0 years.
Instem is assigned to the 'Health' sector.
The dividends of Instem are distributed in GBP.
Instem stock
Instem Peer Group
Instem Ticker
Instem FIGI
All fundamentals and in-depth analysis of Instem
Our stock analysis for Instem stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Instem. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.